markusathome
@markusathome.bsky.social
www.youtube.com/@MarkusAtHome
Tonight: Antithrombotic Therapy in ASCVD + VTE: AQUATIC - Prof. Behnood Bikdeli, Prof. Romain Didier
youtu.be/w8qCX2pRSxQ?...
@bbikdeli.bsky.social
youtu.be/w8qCX2pRSxQ?...
@bbikdeli.bsky.social
Antithrombotic Therapy in ASCVD + VTE: AQUATIC - Prof. Behnood Bikdeli, Prof. Romain Didier
YouTube video by MARKUS at HOMe
youtu.be
December 5, 2025 at 3:59 PM
Tonight: Antithrombotic Therapy in ASCVD + VTE: AQUATIC - Prof. Behnood Bikdeli, Prof. Romain Didier
youtu.be/w8qCX2pRSxQ?...
@bbikdeli.bsky.social
youtu.be/w8qCX2pRSxQ?...
@bbikdeli.bsky.social
VALIANT: Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN by Drs. Fakhouri, Nester et al.
www.nejm.org/doi/full/10....
Pegcetacoplan resulted in a significantly greater reduction in proteinuria than placebo among patients with C3 GN or primary immune-complex MPGN.
www.nejm.org/doi/full/10....
Pegcetacoplan resulted in a significantly greater reduction in proteinuria than placebo among patients with C3 GN or primary immune-complex MPGN.
Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN | NEJM
C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis (MPGN) generally result in glomerular C3 deposition and irreversible kidney damage. The efficacy and safety of ...
www.nejm.org
December 4, 2025 at 8:01 PM
VALIANT: Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN by Drs. Fakhouri, Nester et al.
www.nejm.org/doi/full/10....
Pegcetacoplan resulted in a significantly greater reduction in proteinuria than placebo among patients with C3 GN or primary immune-complex MPGN.
www.nejm.org/doi/full/10....
Pegcetacoplan resulted in a significantly greater reduction in proteinuria than placebo among patients with C3 GN or primary immune-complex MPGN.
Trends in CVE & Bleeding in Advanced CKD: SRR - Dr. M. Evans, Dr. A.-L. Faucon (Stockholm, Sweden)
youtu.be/S2hbWPWkzcU?...
youtu.be/S2hbWPWkzcU?...
Trends in CVE & Bleeding in Advanced CKD: SRR - Dr. M. Evans, Dr. A.-L. Faucon (Stockholm, Sweden)
YouTube video by MARKUS at HOMe
youtu.be
November 28, 2025 at 6:55 PM
Trends in CVE & Bleeding in Advanced CKD: SRR - Dr. M. Evans, Dr. A.-L. Faucon (Stockholm, Sweden)
youtu.be/S2hbWPWkzcU?...
youtu.be/S2hbWPWkzcU?...
High-Dose vs Standard-Dose Influenza Vaccine in Chronic Kidney Disease by Drs. Bartholdy, Biering-Sørensen et al.
www.jacc.org/doi/10.1016/...
In this prespecified analysis of DANFLU-2 a benefit of HD-IIV over SD-IIV was observed.
www.jacc.org/doi/10.1016/...
In this prespecified analysis of DANFLU-2 a benefit of HD-IIV over SD-IIV was observed.
November 27, 2025 at 8:33 PM
High-Dose vs Standard-Dose Influenza Vaccine in Chronic Kidney Disease by Drs. Bartholdy, Biering-Sørensen et al.
www.jacc.org/doi/10.1016/...
In this prespecified analysis of DANFLU-2 a benefit of HD-IIV over SD-IIV was observed.
www.jacc.org/doi/10.1016/...
In this prespecified analysis of DANFLU-2 a benefit of HD-IIV over SD-IIV was observed.
Extended DOAC Therapy in Provoked VTE - HI-PRO - Prof. Behnood Bikdeli, Prof. Romain Didier
@bbikdeli.bsky.social
youtu.be/e0Orc_Ps56U?...
@bbikdeli.bsky.social
youtu.be/e0Orc_Ps56U?...
Extended DOAC Therapy in Provoked VTE - HI-PRO - Prof. Behnood Bikdeli, Prof. Romain Didier
YouTube video by MARKUS at HOMe
youtu.be
November 21, 2025 at 7:39 PM
Extended DOAC Therapy in Provoked VTE - HI-PRO - Prof. Behnood Bikdeli, Prof. Romain Didier
@bbikdeli.bsky.social
youtu.be/e0Orc_Ps56U?...
@bbikdeli.bsky.social
youtu.be/e0Orc_Ps56U?...
Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD)
by Drs. Johansen, Biering-Sørensen et al.
www.thelancet.com/journals/lan...
In this analysis, HD-IIV demonstrated superior protection compared with SD-IIV.
by Drs. Johansen, Biering-Sørensen et al.
www.thelancet.com/journals/lan...
In this analysis, HD-IIV demonstrated superior protection compared with SD-IIV.
November 20, 2025 at 7:40 PM
Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD)
by Drs. Johansen, Biering-Sørensen et al.
www.thelancet.com/journals/lan...
In this analysis, HD-IIV demonstrated superior protection compared with SD-IIV.
by Drs. Johansen, Biering-Sørensen et al.
www.thelancet.com/journals/lan...
In this analysis, HD-IIV demonstrated superior protection compared with SD-IIV.
Immune Checkpoint Inhibitor–Associated Cardiovascular Toxic Effects by Drs. Herrmann, Mitchell et al.
An International Cardio-Oncology Society Position Statement:
jamanetwork.com/journals/jam...
An International Cardio-Oncology Society Position Statement:
jamanetwork.com/journals/jam...
November 18, 2025 at 7:16 PM
Immune Checkpoint Inhibitor–Associated Cardiovascular Toxic Effects by Drs. Herrmann, Mitchell et al.
An International Cardio-Oncology Society Position Statement:
jamanetwork.com/journals/jam...
An International Cardio-Oncology Society Position Statement:
jamanetwork.com/journals/jam...
Deferring Arterial Catheterization in Critically Ill Patients with Shock by Drs. Muller, Boulain et al.
www.nejm.org/doi/pdf/10.1...
Results for death from any cause at day 28 indicated that management without early arterial cath. insertion was noninferior to early cath. insertion.
www.nejm.org/doi/pdf/10.1...
Results for death from any cause at day 28 indicated that management without early arterial cath. insertion was noninferior to early cath. insertion.
November 16, 2025 at 5:40 PM
Deferring Arterial Catheterization in Critically Ill Patients with Shock by Drs. Muller, Boulain et al.
www.nejm.org/doi/pdf/10.1...
Results for death from any cause at day 28 indicated that management without early arterial cath. insertion was noninferior to early cath. insertion.
www.nejm.org/doi/pdf/10.1...
Results for death from any cause at day 28 indicated that management without early arterial cath. insertion was noninferior to early cath. insertion.
Couldn't be there live? No problem, here are the highlights!
Kongressupdate AHA / ASN 2025
youtu.be/pM956An3wJ8?...
@asnkidney.bsky.social @ahascience.bsky.social
Kongressupdate AHA / ASN 2025
youtu.be/pM956An3wJ8?...
@asnkidney.bsky.social @ahascience.bsky.social
Kongressupdate AHA / ASN 2025
YouTube video by MARKUS at HOMe
youtu.be
November 14, 2025 at 6:56 PM
Couldn't be there live? No problem, here are the highlights!
Kongressupdate AHA / ASN 2025
youtu.be/pM956An3wJ8?...
@asnkidney.bsky.social @ahascience.bsky.social
Kongressupdate AHA / ASN 2025
youtu.be/pM956An3wJ8?...
@asnkidney.bsky.social @ahascience.bsky.social
A Conservative Dialysis Strategy and Kidney Function Recovery in Dialysis-Requiring Acute Kidney Injury:
LIBERATE-D by Drs. Liu, Hsu et al.
jamanetwork.com/journals/jam...
A conservative dialysis strategy promoted recovery from dialysis-requiring acute kidney injury.
LIBERATE-D by Drs. Liu, Hsu et al.
jamanetwork.com/journals/jam...
A conservative dialysis strategy promoted recovery from dialysis-requiring acute kidney injury.
November 11, 2025 at 6:50 PM
A Conservative Dialysis Strategy and Kidney Function Recovery in Dialysis-Requiring Acute Kidney Injury:
LIBERATE-D by Drs. Liu, Hsu et al.
jamanetwork.com/journals/jam...
A conservative dialysis strategy promoted recovery from dialysis-requiring acute kidney injury.
LIBERATE-D by Drs. Liu, Hsu et al.
jamanetwork.com/journals/jam...
A conservative dialysis strategy promoted recovery from dialysis-requiring acute kidney injury.
What an exciting weekend... So many new studies to discuss!
November 9, 2025 at 6:28 PM
What an exciting weekend... So many new studies to discuss!
ESC Dyslipidemia Guidelines - 2025 Update - Prof. Dr. François Mach, Geneva, Switzerland
youtu.be/-y_ma-kW61o?...
Prof. Mach presents the 2025 Focused Update of the European Guidelines for the management of dyslipidaemias, which have been published by @escardio.bsky.social @eassociety.bsky.social.
youtu.be/-y_ma-kW61o?...
Prof. Mach presents the 2025 Focused Update of the European Guidelines for the management of dyslipidaemias, which have been published by @escardio.bsky.social @eassociety.bsky.social.
ESC Dyslipidemia Guidelines - 2025 Update - Prof. Dr. François Mach, Geneva, Switzerland
YouTube video by MARKUS at HOMe
youtu.be
November 7, 2025 at 6:43 PM
ESC Dyslipidemia Guidelines - 2025 Update - Prof. Dr. François Mach, Geneva, Switzerland
youtu.be/-y_ma-kW61o?...
Prof. Mach presents the 2025 Focused Update of the European Guidelines for the management of dyslipidaemias, which have been published by @escardio.bsky.social @eassociety.bsky.social.
youtu.be/-y_ma-kW61o?...
Prof. Mach presents the 2025 Focused Update of the European Guidelines for the management of dyslipidaemias, which have been published by @escardio.bsky.social @eassociety.bsky.social.
Rituximab for Relapsing Nephrotic Syndrome in Adults by Drs. Isaka, Hiromura et al.
jamanetwork.com/journals/jam...
The relapse-free rate at week 49 was 87.4%(95% CI, 69.8%-95.1%) in the rituximab group and 38.0%(95% CI, 22.1%-53.8%) in the placebo group.
jamanetwork.com/journals/jam...
The relapse-free rate at week 49 was 87.4%(95% CI, 69.8%-95.1%) in the rituximab group and 38.0%(95% CI, 22.1%-53.8%) in the placebo group.
November 6, 2025 at 6:53 PM
Rituximab for Relapsing Nephrotic Syndrome in Adults by Drs. Isaka, Hiromura et al.
jamanetwork.com/journals/jam...
The relapse-free rate at week 49 was 87.4%(95% CI, 69.8%-95.1%) in the rituximab group and 38.0%(95% CI, 22.1%-53.8%) in the placebo group.
jamanetwork.com/journals/jam...
The relapse-free rate at week 49 was 87.4%(95% CI, 69.8%-95.1%) in the rituximab group and 38.0%(95% CI, 22.1%-53.8%) in the placebo group.
Short-Term Anticoagulation versus DAPT for Preventing Device Thrombosis Following LAAC: The ANDES RCT by Drs. Rodés-Cabau, Salaun et al.
www.ahajournals.org/doi/10.1161/...
The use of DOAC after LAAC failed to reduce DRT compared to DAPT but it was associated with an improved safety profile.
www.ahajournals.org/doi/10.1161/...
The use of DOAC after LAAC failed to reduce DRT compared to DAPT but it was associated with an improved safety profile.
November 4, 2025 at 6:30 PM
Short-Term Anticoagulation versus DAPT for Preventing Device Thrombosis Following LAAC: The ANDES RCT by Drs. Rodés-Cabau, Salaun et al.
www.ahajournals.org/doi/10.1161/...
The use of DOAC after LAAC failed to reduce DRT compared to DAPT but it was associated with an improved safety profile.
www.ahajournals.org/doi/10.1161/...
The use of DOAC after LAAC failed to reduce DRT compared to DAPT but it was associated with an improved safety profile.
Stream it now! Our webinar in cooperation with NDT:
IgA-NP: Treatment Standard & Future Perspective - Prof. Jonathan Barratt, Prof. Jai Radhakrishnan
@ndt-era.bsky.social @kronbichlerlab.bsky.social @gunnarheine.bsky.social @hjanders.bsky.social
youtu.be/l0g9_lkW5_w?...
IgA-NP: Treatment Standard & Future Perspective - Prof. Jonathan Barratt, Prof. Jai Radhakrishnan
@ndt-era.bsky.social @kronbichlerlab.bsky.social @gunnarheine.bsky.social @hjanders.bsky.social
youtu.be/l0g9_lkW5_w?...
IgA-NP: Treatment Standard & Future Perspective - Prof. Jonathan Barratt, Prof. Jai Radhakrishnan
YouTube video by MARKUS at HOMe
youtu.be
October 31, 2025 at 6:21 PM
Stream it now! Our webinar in cooperation with NDT:
IgA-NP: Treatment Standard & Future Perspective - Prof. Jonathan Barratt, Prof. Jai Radhakrishnan
@ndt-era.bsky.social @kronbichlerlab.bsky.social @gunnarheine.bsky.social @hjanders.bsky.social
youtu.be/l0g9_lkW5_w?...
IgA-NP: Treatment Standard & Future Perspective - Prof. Jonathan Barratt, Prof. Jai Radhakrishnan
@ndt-era.bsky.social @kronbichlerlab.bsky.social @gunnarheine.bsky.social @hjanders.bsky.social
youtu.be/l0g9_lkW5_w?...
Sodium Bicarbonate for Severe Metabolic Acidemia and Acute Kidney Injury
The BICARICU-2 Randomized Clinical Trial
by Drs. Jung, Jaber et al.
jamanetwork.com/journals/jam...
In this randomized trial infusion of sodium bicarbonate did not improve 90-day mortality.
The BICARICU-2 Randomized Clinical Trial
by Drs. Jung, Jaber et al.
jamanetwork.com/journals/jam...
In this randomized trial infusion of sodium bicarbonate did not improve 90-day mortality.
October 30, 2025 at 8:58 PM
Sodium Bicarbonate for Severe Metabolic Acidemia and Acute Kidney Injury
The BICARICU-2 Randomized Clinical Trial
by Drs. Jung, Jaber et al.
jamanetwork.com/journals/jam...
In this randomized trial infusion of sodium bicarbonate did not improve 90-day mortality.
The BICARICU-2 Randomized Clinical Trial
by Drs. Jung, Jaber et al.
jamanetwork.com/journals/jam...
In this randomized trial infusion of sodium bicarbonate did not improve 90-day mortality.
Urinary tract infection and continuation of SGLT-I in diabetic patients by Drs. Wu, Yiu et al.
academic.oup.com/eurheartj/ar...
Discontinuing SGLT2 inhibitors after a UTI was linked to a higher risk of cardiovascular and renal outcomes but was not associated with fewer recurrent UTI.
academic.oup.com/eurheartj/ar...
Discontinuing SGLT2 inhibitors after a UTI was linked to a higher risk of cardiovascular and renal outcomes but was not associated with fewer recurrent UTI.
October 28, 2025 at 7:50 PM
Urinary tract infection and continuation of SGLT-I in diabetic patients by Drs. Wu, Yiu et al.
academic.oup.com/eurheartj/ar...
Discontinuing SGLT2 inhibitors after a UTI was linked to a higher risk of cardiovascular and renal outcomes but was not associated with fewer recurrent UTI.
academic.oup.com/eurheartj/ar...
Discontinuing SGLT2 inhibitors after a UTI was linked to a higher risk of cardiovascular and renal outcomes but was not associated with fewer recurrent UTI.
Our experts explain:
CKD of unexplained cause: ERA G & K Consensus - Prof. @ecorneclegall.bsky.social, Prof. Halbritter, Prof. Müller
youtu.be/RzupTGtHs8g?...
They present the CKDx consensus statement of the ERA Genes & Kidney Working Group, published in NDT.
CKD of unexplained cause: ERA G & K Consensus - Prof. @ecorneclegall.bsky.social, Prof. Halbritter, Prof. Müller
youtu.be/RzupTGtHs8g?...
They present the CKDx consensus statement of the ERA Genes & Kidney Working Group, published in NDT.
CKD of unexplained cause: ERA G & K Consensus - Prof. Cornec-Le Gall, Prof. Halbritter, Prof. Müller
YouTube video by MARKUS at HOMe
youtu.be
October 24, 2025 at 6:35 PM
Our experts explain:
CKD of unexplained cause: ERA G & K Consensus - Prof. @ecorneclegall.bsky.social, Prof. Halbritter, Prof. Müller
youtu.be/RzupTGtHs8g?...
They present the CKDx consensus statement of the ERA Genes & Kidney Working Group, published in NDT.
CKD of unexplained cause: ERA G & K Consensus - Prof. @ecorneclegall.bsky.social, Prof. Halbritter, Prof. Müller
youtu.be/RzupTGtHs8g?...
They present the CKDx consensus statement of the ERA Genes & Kidney Working Group, published in NDT.
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus by Drs. van Vollenhoven, Zhang et al.
www.nejm.org/doi/full/10....
The incidence of a clinical response was higher with telitacicept (a new dual inhibitor of the cytokines B-lymphocyte stimulator and APRIL) than with placebo.
www.nejm.org/doi/full/10....
The incidence of a clinical response was higher with telitacicept (a new dual inhibitor of the cytokines B-lymphocyte stimulator and APRIL) than with placebo.
October 23, 2025 at 5:47 PM
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus by Drs. van Vollenhoven, Zhang et al.
www.nejm.org/doi/full/10....
The incidence of a clinical response was higher with telitacicept (a new dual inhibitor of the cytokines B-lymphocyte stimulator and APRIL) than with placebo.
www.nejm.org/doi/full/10....
The incidence of a clinical response was higher with telitacicept (a new dual inhibitor of the cytokines B-lymphocyte stimulator and APRIL) than with placebo.
Novel developments in the treatment of HFrEF - Prof. Dr. John McMurray (Glasgow, UK)
youtu.be/kK8N-5RkEfc?...
Prof. McMurray discusses new developments in the treatment of HFrEF, focusing on new outcome data for vericiguat and digitoxin from the VICTOR and DIGIT-HF studies.
youtu.be/kK8N-5RkEfc?...
Prof. McMurray discusses new developments in the treatment of HFrEF, focusing on new outcome data for vericiguat and digitoxin from the VICTOR and DIGIT-HF studies.
Novel developments in the treatment of HFREF - Prof. Dr. John McMurray (Glasgow, UK)
YouTube video by MARKUS at HOMe
youtu.be
October 17, 2025 at 6:02 PM
Novel developments in the treatment of HFrEF - Prof. Dr. John McMurray (Glasgow, UK)
youtu.be/kK8N-5RkEfc?...
Prof. McMurray discusses new developments in the treatment of HFrEF, focusing on new outcome data for vericiguat and digitoxin from the VICTOR and DIGIT-HF studies.
youtu.be/kK8N-5RkEfc?...
Prof. McMurray discusses new developments in the treatment of HFrEF, focusing on new outcome data for vericiguat and digitoxin from the VICTOR and DIGIT-HF studies.
Fractional flow reserve-guided renal artery stenting in atherosclerotic renovascular hypertension: the FAIR randomized trial by Drs. Li, Li et al.
academic.oup.com/eurheartj/ar...
BP and antihypertensive medication usage decreased significantly after stenting in patients with FFR < 0.80
academic.oup.com/eurheartj/ar...
BP and antihypertensive medication usage decreased significantly after stenting in patients with FFR < 0.80
October 16, 2025 at 6:48 PM
Fractional flow reserve-guided renal artery stenting in atherosclerotic renovascular hypertension: the FAIR randomized trial by Drs. Li, Li et al.
academic.oup.com/eurheartj/ar...
BP and antihypertensive medication usage decreased significantly after stenting in patients with FFR < 0.80
academic.oup.com/eurheartj/ar...
BP and antihypertensive medication usage decreased significantly after stenting in patients with FFR < 0.80
Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes by Drs. Herrington, Staplin et al.
www.sciencedirect.com/science/arti...
SGLT2 I reduces the risk of acute and chronic kidney outcomes irrespective of the size of the acute dip in eGFR.
www.sciencedirect.com/science/arti...
SGLT2 I reduces the risk of acute and chronic kidney outcomes irrespective of the size of the acute dip in eGFR.
October 14, 2025 at 7:48 PM
Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes by Drs. Herrington, Staplin et al.
www.sciencedirect.com/science/arti...
SGLT2 I reduces the risk of acute and chronic kidney outcomes irrespective of the size of the acute dip in eGFR.
www.sciencedirect.com/science/arti...
SGLT2 I reduces the risk of acute and chronic kidney outcomes irrespective of the size of the acute dip in eGFR.
SGLT-2 Inhibition in ADPKD? DAPA-PKD & STOP-PKD - Prof. Emilie Cornec Le Gall & Prof. Roman-Ulrich Müller
youtu.be/9e-UFBnIyDI?...
@ecorneclegall.bsky.social @muellerrom.bsky.social @kronbichlerlab.bsky.social @sarahelena.bsky.social @gunnarheine.bsky.social @marcussaemann.bsky.social
youtu.be/9e-UFBnIyDI?...
@ecorneclegall.bsky.social @muellerrom.bsky.social @kronbichlerlab.bsky.social @sarahelena.bsky.social @gunnarheine.bsky.social @marcussaemann.bsky.social
SGLT-2 I in ADPKD? DAPA-PKD & STOP-PKD - Prof. Emilie Cornec Le Gall & Prof. Roman-Ulrich Müller
YouTube video by MARKUS at HOMe
youtu.be
October 10, 2025 at 6:21 PM
SGLT-2 Inhibition in ADPKD? DAPA-PKD & STOP-PKD - Prof. Emilie Cornec Le Gall & Prof. Roman-Ulrich Müller
youtu.be/9e-UFBnIyDI?...
@ecorneclegall.bsky.social @muellerrom.bsky.social @kronbichlerlab.bsky.social @sarahelena.bsky.social @gunnarheine.bsky.social @marcussaemann.bsky.social
youtu.be/9e-UFBnIyDI?...
@ecorneclegall.bsky.social @muellerrom.bsky.social @kronbichlerlab.bsky.social @sarahelena.bsky.social @gunnarheine.bsky.social @marcussaemann.bsky.social
The relationship between obesity and chronic kidney disease: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
by Drs. Furth, Rossing et al.
www.kidney-international.org/article/S008...
by Drs. Furth, Rossing et al.
www.kidney-international.org/article/S008...
October 9, 2025 at 6:49 PM
The relationship between obesity and chronic kidney disease: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
by Drs. Furth, Rossing et al.
www.kidney-international.org/article/S008...
by Drs. Furth, Rossing et al.
www.kidney-international.org/article/S008...
Transthyretin amyloid cardiomyopathy: from cause to novel treatments by Drs. Fontana, Gillmore et al.
academic.oup.com/eurheartj/ar...
academic.oup.com/eurheartj/ar...
October 7, 2025 at 6:58 PM
Transthyretin amyloid cardiomyopathy: from cause to novel treatments by Drs. Fontana, Gillmore et al.
academic.oup.com/eurheartj/ar...
academic.oup.com/eurheartj/ar...